

Applicants: David M. Stern, et al.  
U.S. Serial No.: 08/905,709  
Filed: August 5, 1997  
Page 3

Please replace the paragraph that appears on page 8, lines 10-14 with the following paragraph:

63 The soluble receptor for advanced glycation endproduct (sRAGE) polypeptide may be administered hourly, daily, weekly, monthly, yearly (e.g. in a time release form) or as a one time delivery. The delivery or administration may be continuous delivery for a period of time (e.g. intravenous delivery).

REMARKS

Claims 1-10, 12, 13, 15-27, 29, 30, 32-39 and 46 are pending and under examination. Applicants have amended the specification in order to introduce certain grammatical and format changes. Applicants maintain that these amendments raise no issue of new matter, and respectfully request entry of this Preliminary Amendment. Upon entry of this Preliminary Amendment, claims 1-10, 12, 13, 15-27, 29, 30, 32-39 and 46 will still be pending and under examination.

Pursuant to the requirements of 37 C.F.R. 1.121(b)(2), applicants annex hereto as Exhibit A the amended paragraphs of the specification marked up to show the changes made herein relative to the previous versions thereof.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorneys invite the Examiner to telephone them at the number provided below.

Applicants: David M. Stern, et al.  
U.S. Serial No.: 08/905,709  
Filed: August 5, 1997  
Page 4

No fee, other than the enclosed \$840.00, is deemed necessary. However, if any additional fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,



---

John P. White  
Registration No. 28,678  
Alan J. Morrison  
Registration No. 37,399  
Attorneys for Applicants  
Cooper & Dunham LLP  
1185 Avenue of the Americas  
New York, New York 10036  
Tel. No. (212) 278-0400

Marked-Up Version of Amended Paragraphs

Page 2, lines 12-23:

The reasons for accelerated atherosclerosis in the setting of diabetes are numerous. However, even after correction for dyslipidemia, hypertension and obesity, multivariate analysis studies have indicated that diabetic [patient] subjects have an excess risk of cardiovascular disease relative to nondiabetic subjects (Kannel and McGee, 1979). For example, in the Nurses' Health Study of 1,500 diabetic subjects among a total of 115,000 women, the incidence of cardiovascular disease was 5-fold higher in the diabetic subjects regardless of their levels of cholesterol (Manson et al., 1991). These data suggest that factors unique to the diabetic population play an important role.

Page 7, lines 25-30:

The polypeptide may comprise a 10 kilodalton domain of naturally occurring soluble receptor for advanced glycation endproduct. The polypeptide may [comprises] comprise less than or equal to 20 amino acids in length which [sequence is] sequences are within the sequence of the naturally occurring soluble receptor for advanced glycation endproduct.

Page 8, lines 10-14:

The [sRAGE] soluble receptor for advanced glycation endproduct (sRAGE) polypeptide may be administered hourly, daily, weekly, monthly, yearly (e.g. in a time release form) or as a one time delivery. The delivery or administration may be continuous delivery for a period of time (e.g. intravenous delivery).